Zoloft To Be Dropped From WellPoint, Medco Part D Formularies
Executive Summary
WellPoint and Medco are planning to remove Pfizer's Zoloft from their Part D formularies once a generic version of the antidepressant becomes available, according to the companies. The drug's patent expired on June 30 and FDA announced its approval of a generic the same day